


DRUG TREATMENTS FOR ADULTS WITH COVID-19

IMPORTANT
This information is no longer being updated. Users acknowledge that this information may not be accurate, relevant or complete



VERSION 19.0
PUBLISHED 27 MARCH 2023

		Not requiring oxygen WITHOUT lower respiratory tract disease	Not requiring oxygen WITH lower respiratory tract disease	Requiring oxygen WITHOUT mechanical ventilation	Requiring invasive mechanical ventilation
DEFINITION OF DISEASE SEVERITY	RECOMMENDED	Mild An individual with no clinical features suggestive of moderate or more severe disease: • no OR mild symptoms and signs (fever, cough, sore throat, malaise, headache, muscle pain, nausea, vomiting, diarrhoea, loss of taste and smell) • no new shortness of breath or difficulty breathing on exertion • no evidence of lower respiratory tract disease during clinical assessment or on imaging (if performed)	Moderate A stable patient with evidence of lower respiratory tract disease: • during clinical assessment, such as – oxygen saturation 92-94% on room air at rest – desaturation or breathlessness with mild exertion • or on imaging	Severe A patient with signs of moderate disease who is deteriorating OR A patient meeting any of the following criteria: • respiratory rate ≥30 breaths/min • oxygen saturation <92% on room air at rest or requiring oxygen • lung infiltrates >50%	Critical A patient meeting any of the following criteria: • respiratory failure (defined as any of) – severe respiratory failure (PaO₂/ FiO₂ <200) – respiratory distress or acute respiratory distress syndrome (ARDS) – deteriorating despite non-invasive forms of respiratory support (i.e. non-invasive ventilation (NIV), or high-flow nasal oxygen (HFNO)) – requiring mechanical ventilation • hypotension or shock • impairment of consciousness • other organ failure
		Use intravenous or oral dexamethasone for up to 10 days (or acceptable alternative regimen) in adults with COVID-19 who require oxygen (including mechanically ventilated patients).			
CONDITIONAL RECOMMENDATION FOR	Consider using inhaled corticosteroids (budesonide or ciclesonide) within 14 days of symptom onset in adults with COVID-19 who do not require oxygen and who have one or more risk factors [^] for disease progression.				
	Consider using one of the following: Consider using remdesivir within 7 days of symptom onset in unvaccinated [#] adults with COVID-19 who do not require oxygen and who have one or more risk factors [^] for disease progression. Within the patient population for which remdesivir is conditionally recommended for use (see Remark), decisions about the appropriateness of treatment with remdesivir should be based on the patient's individual risk of severe disease, including their age, presence of multiple risk factors, and vaccination status (including number of doses and time since last dose / or timing of most recent infection). <i>Note: Refer to the related consensus recommendation below for additional guidance.</i>		Consider using remdesivir in adults with COVID-19 who require oxygen but do not require non-invasive or invasive ventilation .		
	Consider using nirmatrelvir plus ritonavir (Paxlovid) ^{**} within 5 days of symptom onset in unvaccinated [#] adults with COVID-19 who do not require oxygen and who have one or more risk factors [^] for disease progression. Within the patient population for which nirmatrelvir plus ritonavir is conditionally recommended for use (see Remark), decisions about the appropriateness of treatment with nirmatrelvir plus ritonavir should be based on the patient's individual risk of severe disease, including their age, presence of multiple risk factors, and vaccination status (including number of doses and time since last dose/ or timing of most recent infection). <i>Note: Refer to the related consensus recommendation below for additional guidance.</i>		Consider using one of the following ^{##} : Consider using tocilizumab for the treatment of COVID-19 in adults who require supplemental oxygen , particularly where there is evidence of systemic inflammation . Consider using baricitinib in adults hospitalised with COVID-19 who require supplemental oxygen . [*] Consider using abatacept for the treatment of COVID-19 in adults who require supplemental oxygen but not mechanical ventilation or ECMO, particularly where there is evidence of systemic inflammation . Consider using infliximab for the treatment of COVID-19 in adults who require supplemental oxygen but not mechanical ventilation or ECMO, particularly where there is evidence of systemic inflammation .		

Note: Sarilumab can be used in adults who require high-flow oxygen, non-invasive ventilation or invasive mechanical ventilation but has been omitted because it is not easily accessible in Australia.

	Not requiring oxygen WITHOUT lower respiratory tract disease	Not requiring oxygen WITH lower respiratory tract disease	Requiring oxygen WITHOUT mechanical ventilation	Requiring invasive mechanical ventilation
CONSENSUS RECOMMENDATION FOR	In addition to at-risk unvaccinated adults, also consider using remdesivir within 7 days of symptom onset in adults with COVID-19 who do not require oxygen and are immunocompromised; or are at particularly high risk of severe disease on the basis of advanced age and multiple risk factors^. In addition to at-risk unvaccinated adults, also consider using nirmatrelvir plus ritonavir (Paxlovid)** within 5 days of symptom onset in adults with COVID-19 who do not require oxygen and are immunocompromised; or are at particularly high risk of severe disease on the basis of advanced age and multiple risk factors^.			
CONSENSUS RECOMMENDATION AGAINST	Do not routinely use the following monoclonal antibodies for the treatment of COVID-19: - casirivimab plus imdecimab (Ronapreve) - sotrovimab (Xevudy) - regdanvimab (Regkirona) - tixagevimab plus cilgavimab (Evusheld) *It is unlikely that tixagevimab plus cilgavimab (Evusheld) is effective in treating individuals with currently circulating variants of COVID-19. Use may be considered for people infected with known Omicron BA2.			
CONDITIONAL RECOMMENDATION AGAINST	Do not routinely use molnupiravir for the treatment of COVID-19. Do not routinely use dexamethasone (or other systemic corticosteroid) to treat COVID-19 in adults who do not require oxygen.			
NOT RECOMMENDED	DO NOT use the following for the treatment of COVID-19: - aspirin - azithromycin - colchicine - hydroxychloroquine - hydroxychloroquine plus azithromycin - interferon β-1a - interferon β-1a plus lopinavir-ritonavir - ivermectin - lopinavir-ritonavir DO NOT use convalescent plasma for the treatment of COVID-19 in patients who require supplemental oxygen. DO NOT start remdesivir in adults hospitalised with COVID-19 who require non-invasive or invasive ventilation.			
ONLY IN RESEARCH	Do not use convalescent plasma for the treatment of COVID-19 in patients who do not require oxygen outside of randomised trials with appropriate ethical approval. Do not use the following for the treatment of COVID-19 outside of randomised trials with appropriate ethical approval: - almitrine - anakinra - angiotensin 2 receptor agonist C21 - aprepitant - baloxavir marboxil - bamlanivimab - bamlanivimab plus etesevimab - bebtelovimab - bromhexine hydrochloride - camostat mesilate - CD24Fc - chloroquine - combined metabolic activators (CMA) - darunavir-cobicistat - doxycycline - dutasteride - enisamium - ensovibep - fluvoxamine - human umbilical cord mesenchymal stem cells - hyperbaric oxygen therapy - immunoglobulin - immunoglobulin plus methylprednisone - inhaled interferon β-1a - interferon β-1b - interferon gamma - interferon kappa plus trefoil factor 2 (IFN-k plus TFF2) - ivermectin plus doxycycline - lenzilumab - metformin - N-acetylcysteine - naltrexone - nitazoxanide - opaganib - peginterferon lambda - recombinant human granulocyte colony-stimulating factor (rhG-CSF) - ruxolitinib - sabizabulin - sofosbuvir-daclatasvir - sulodexide - telmisartan - tofacitinib - triazavirin - umifenovir - vitamin C - vitamin D analogues (calcifediol / cholecalciferol) - zinc - other disease-modifying treatments			

Please refer to footnotes located on page 3 of this flowchart.

- Immunocompromising conditions** include:
- Primary or acquired immunodeficiency
 - Haematologic neoplasms: leukaemias, lymphomas, myelodysplastic syndromes
 - Post-transplant: solid organ (on immunosuppressive therapy), haematopoietic stem cell transplant (within 24 months)
 - Immunocompromised due to primary or acquired (AIDS) immunodeficiency
 - Other significantly immunocompromising conditions
 - Immunosuppressive therapy (current or recent)
 - Chemotherapy, whole body radiotherapy or total lymphoid irradiation
 - High-dose corticosteroids (≥20 mg of prednisone per day, or equivalent) for ≥14 days
 - Selected other potent immunosuppressive therapies (refer to [ATAGI advice](#))

Refer to the **Risk Classification Tool** when making decisions about which individuals are most likely to benefit from treatment.

- Risk factors for disease progression**
- Older age (e.g. over 65 years, or over 50 years for Aboriginal and Torres Strait Islander people)
 - Diabetes requiring medication
 - Obesity (BMI >30 kg/m²)
 - Renal failure
 - Cardiovascular disease, including hypertension
 - Respiratory compromise, including COPD, asthma requiring steroids, or bronchiectasis
 - Immunocompromising condition
- Note: This list has been simplified based on the individual risk factors for each therapy option from clinical trial evidence. Refer to the [Australian guidelines for the clinical care of people with COVID-19](#) for further information.*

Refer to the [Decision Support Tool](#) for specific guidance on drug treatments for at risk adults with COVID-19 who do not require oxygen.

Source
National Clinical Evidence Taskforce – Australian guidelines for the clinical care of people with COVID-19.

Note: This flowchart does not apply to people on home oxygen due to pre-existing conditions. Rely on clinical judgement in these cases.

Efficacy is unclear in individuals who have received any COVID-19 vaccine.
** Check for common, serious drug-drug interactions before prescribing and administering nirmatrelvir plus ritonavir with other medications.
The RECOVERY trial has demonstrated a benefit when using tocilizumab in conjunction with baricitinib, however there are limited data available to evaluate the safety of this combination. The RECOVERY trial has also demonstrated a benefit when using baricitinib in conjunction with corticosteroids, tocilizumab or remdesivir, however the Taskforce notes that the concomitant use of two or more immunomodulatory agents may increase the risk of side effects such as opportunistic infection.